We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 355

SCOTUS sides with FTC in reverse payment deals
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

A divided U.S. Supreme Court has determined that patent-infringement settlement agreements requiring the patentee to pay the claimed infringer


Biotech set to raise $86 million in IPO to support cancer and IEM products
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

Agios Pharmaceuticals, Inc. has filed a registration statement with the U.S. Securities and Exchange Commission indicating its intent to raise up to


Lab Trade Association presses FDA on plan to regulate laboratory developed tests
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

The American Clinical Laboratory Association (ACLA) has submitted a citizen petition to the Food and Drug Administration (FDA), asking the agency to


Neumedicines receives $8.3 million from BARDA for radiation sickness drug
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

Pasadena-based Neumedicines Inc. has reportedly received $8.3 million from the Biomedical Advanced Research & Development Authority (BARDA) of the U


U.S. Supreme Court issues ruling on patentability of human genes
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

The U.S. Supreme Court has determined that while human genes and the information they encode are not patent eligible, despite the effort required to


Biopharmaceutical companies have 215 heart diseasestroke drugs in R&D pipeline
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

According to a new Pharmaceutical Research and Manufacturers of America (PhRMA) report, U.S. biopharmaceutical companies have 215 medicines under


FDA seeks comments on de-identified and masked data
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

The U.S. Food and Drug Administration (FDA) has issued a notice seeking comments on "the proposed availability of de-identified and masked data


President’s Bioethics Commission issues report on pediatric medical testing
  • Shook Hardy & Bacon LLP
  • USA
  • March 21 2013

The Presidential Commission for the Study of Bioethical Issues has issued a report which concludes that "the federal government would have to take


Two Boston-area biotechs set to raise $146 million in IPOs
  • Shook Hardy & Bacon LLP
  • USA
  • March 21 2013

According to a news source, Enanta Pharmaceuticals, Inc. and Tetraphase Pharmaceuticals, Inc. were poised to raise a combined total of $146 million


Active Biotech raises $42.6 million by adding new investor
  • Shook Hardy & Bacon LLP
  • USA
  • March 21 2013

According to news sources, Sweden-based Active Biotech, a developer of treatments for autoimmuneinflammatory diseases and cancer, has nearly doubled